CSRxP Applauds Introduction
of FAST Generics Act
The Campaign for Sustainable Rx Pricing released the following statement from spokesman Will Holley:
“Big Pharma’s longstanding pattern of utilizing the REMS process to forestall generic and biosimilar medications from reaching patients is an anticompetitive and cynical abuse of an important tool for patient safety.
“It is absolutely critical to ensure that medications are utilized safely by those who use them, but it is also enormously important to ensure that medications are affordable to those who need them. The FAST Generics Act represents market-based reforms that will increase competition and ensure that lifesaving medications can safely reach patients at an affordable price.”